Technical report: Congenital adrenal hyperlasia

Pediatrics

Volumn 106, Issue 6, 2000, Pages 1511-1518

  Frias, J ^a   Levine, L S ^a   Oberfield, S E ^a   Pang, S ^a   Silverstein, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CORTICOTROPIN; HYDROCORTISONE; HYDROXYPROGESTERONE; STEROID 21 MONOOXYGENASE;

CHROMOSOME 6; CLINICAL PRACTICE; CONGENITAL ADRENAL HYPERPLASIA; DISEASE ASSOCIATION; GENETIC ANALYSIS; HEALTH CARE POLICY; HUMAN; INFORMATION; MASS SCREENING; PREDICTION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SALT LOSING NEPHRITIS;

EID: 0033673199     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.106.6.1511     Document Type: Review

References (71)

1. Diagnosis of the adrenogenital syndrome before birth
2. Elevated amniotic fluid concentration of 17 alpha-hydroxyprogesterone in congenital adrenal hyperplasia
3. Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency
4. Maternal and amniotic fluid 17 alpha-hydroxyprogesterone levels during pregnancy: Diagnosis of congenital adrenal hyperplasia in utero
5. Prenatal diagnosis of congenital adrenal hyperplasia
6. Antenatal diagnosis of congenital adrenal hyperplasia
7. Prenatal diagnosis of congenital adrenal hyperplasia (21-hydroxylase deficiency) by HLA typing
8. Amniotic fluid concentrations of delta 5 and delta 4 steroids in fetuses with congenital adrenal hyperplasia due to 21 hydroxylase deficiency and in anencephalic fetuses
9. Prenatal diagnosis of congenital adrenal hyperplasia
10. Prenatal diagnosis of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency by steroid analysis in the amniotic fluid of mid-pregnancy: Comparison with HLA typing in 17 pregnancies at risk for CAH
11. Amniotic fluid steroid levels: Fetuses with adrenal hyperplasia, 46, XXY fetuses, and normal fetuses
12. Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency by amniotic fluid steroid analysis
13. Pitfalls of prenatal diagnosis of 21-hydroxylase deficiency congenital adrenal hyperplasia
14. HLA typing of amniotic-fluid cells applied to prenatal diagnosis of congenital adrenal hyperplasia
15. Amniotic 17-alpha hydroxyprogesterone and HLA typing for the prenatal diagnosis of 21-alpha hydroxylase deficiency-congenital adrenal hyperplasia
16. HLA-A,B,C,DR typing and 17-OHP determination for second trimester prenatal diagnosis of 21-hydroxylase deficient CAH
17. Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Up-date 88 of the French multicentric study
18. First trimester prenatal treatment and molecular genetic diagnosis of congenital adrenal hyperplasia (21-hydroxylase deficiency)
19. First trimester prenatal diagnosis of 21-hydroxylase deficiency by linkage analysis to HLA-DNA probes and by 17-hydroxyprogesterone determination
20. Prenatal diagnosis of congenital adrenal hyperplasia
21. The value of chorion villus sampling in early detection of 21-hydroxylase deficiency 21-OHD
22. Treatment of congenital adrenal hyperplasia in utero
23. Prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency
24. Prenatal diagnosis of 21-hydroxylase deficiency congenital adrenal hyperplasia using the polymerase chain reaction
25. Clinical review 54: Genetics, diagnosis, and management of 21-hydroxylase deficiency
26. Molecular genetic prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency by allele-specific hybridization
27. Rapid deoxyribonucleic acid analysis by allele-specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase gene
28. Molecular approaches for the diagnosis of 21-hydroxylase deficiency and congenital adrenal hyperplasia
29. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency
30. Comments about the need for prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency
31. Antenatal diagnosis of adrenocortical hyperplasia
32. Prenatal diagnosis of congenital adrenal hyperplasia
33. Prenatal treatment of congenital adrenal hyperplasia
34. Principles of reproductive embryology
35. Abnormal sex differentiation
36. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency
37. Prenatal treatment of a girl with 21 hydroxylase deficiency
38. Congenital adrenal hyperplasia: Prenatal treatment
39. Successful prenatal treatment of congenital adrenal hyperplasia resulting from the 21-hydroxylase deficiency: Is prenatal diagnosis in a mother at risk essential?
40. Experience with intrauterine therapy of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency
41. Prenatal fetal adrenal suppression following in utero diagnosis of congenital adrenal hyperplasia
42. Prenatal treatment of congenital adrenal hyperplasia: Report of a new case
43. Prenatal treatment of congenital adrenal hyperplasia (CAH): Successful prevention of sexual ambiguity
44. Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia
45. Prenatal diagnosis/treatment in families at risk for infants with steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia)
46. Prenatal diagnosis and successful intrauterine treatment of a female uterus with 21-hydroxylase deficiency
47. Hydrometrocolpos following prenatal dexamethasone treatment for congenital adrenal hyperplasia (21-hydroxylase deficiency)
48. Prenatal treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency: European experience in 223 pregnancies at risk
49. Prenatal diagnosis and treatment of 21-hydroxylase deficiency
50. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency
51. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia
52. Mothers' reactions to prenatal diagnostic procedures and dexamethasone treatment of congenital adrenal hyperplasia
53. Prenatal treatment of congenital adrenal hyperplasia: A promising experimental therapy of unproven safety
54. Magnetic resonance imaging in the congenital adrenal hyperplasia population: Increased frequency of white-matter abnormalities and temporal lobe atrophy
55. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques, I: Hippocampus
56. Glucocorticoid exposure in utero: New model for adult hypertension
57. Prenatal dexamethasone causes oligonephronia, sodium retention, and higher blood pressure in the offspring
58. How safe is long-term prenatal glucocorticoid treatment?
59. Current status of neonatal screening for congenital adrenal hyperplasia
60. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: Its application for rapid screening for congenital adrenal hyperplasia
61. A pilot newborn screening for congenital adrenal hyperplasia in Alaska
62. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder
63. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia
64. Screening for congenital adrenal hyperplasia: The Delfia Screening Test overestimates serum 17-hydroxyprogesterone in preterm infants
65. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels
66. Genotyping CYP21 as an adjunct to hormonal screening of newborns for CAH
67. Home monitoring of 17 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples
68. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia
69. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia
70. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia